Left main coronary artery stenosis treatment with two paclitaxel-eluting stents in a patient with cardiac allograft vasculopathy.
Cardiac transplantation is a well defined therapy for end stage heart failure. After the first year of transplantation, allograft coronary artery disease (ACAD) is the second main cause of death. The ACAD is defined as a diffuse process affecting the entire length of epicardial vessels. Once ACAD has been established, treatments such as coronary angioplasty, coronary stenting, and coronary bypass are performed. We present a case of successful stenting of the left main coronary artery (LMCA) in a patient with ACAD. The patient's medical history was significant for heart transplantation due to ischemic heart failure. Four years after transplantation the patient was admitted again due to sudden worsening of New York Heart Association functional class and extreme fatigue. Coronary angiogram showed a severe stenosis in the proximal segment of the LMCA; we performed stenting with a paclitaxel-eluting stent (PES). Six months after the procedure, the patient had an elective angiogram, where we discovered a new severe occlusion distally to the former stent; a second PES was implanted. Fourteen months after the second stenting, a new elective angiogram was performed without evidence of in-stent restenosis. After a 8-year follow-up since transplantation, the patient is free from dyspnea, angina, and adverse cardiovascular events. Our report suggests the efficacy of PES as ACAD treatment of the unprotected LMCA.
Martínez-Ríos
Marco A
MA
Interventional Cardiology Department, Instituto Nacional de Cardiología, Ignacio Chávez, DF México. mtzrios@cardiologia.org.mx
Méndez-Ortíz
Arturo
A
Gaspar
Jorge
J
Barragán-García
Rodolfo
R
Fernández-de-la-Reguera
Guillermo
G
González-Quesada
Carlos J
CJ
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D023903:Coronary Restenosis / Q000628:therapy; D023921:Coronary Stenosis / Q000188:drug therapy / Q000628:therapy*; D054855:Drug-Eluting Stents; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage*
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel